EAZ171: assessing the best taxane for peripheral neuropathy reduction in breast cancer скачать в хорошем качестве

EAZ171: assessing the best taxane for peripheral neuropathy reduction in breast cancer

Tarah Jean Ballinger, MD, Indiana University School of Medicine, Indianapolis, IN, discusses findings from the EAZ171 trial (NCT04001829), which addresses racial disparities in treatment-induced peripheral neuropathy (TIPN) among Black women receiving weekly paclitaxel versus every three-week docetaxel for early-stage breast cancer. Black women on weekly paclitaxel experienced higher TIPN rates and dose reductions, suggesting docetaxel as a preferred treatment to enhance tolerance and potentially improve outcomes for Black women. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.